A newer treatment approach for AR involves omalizumab, an anti-IgE monoclonal antibody that is widely used to treat allergic asthma through the inhibition of IgE binding to the FcER1 receptor on mast cells and basophils. The gene discussed is IGHE; the disease is allergic asthma.